MAGEC2 and melanoma: An open-label, single-arm, phase II clinical trial evaluated the impact of autologous MoDCs co-electroporated with mRNA molecules coding for four MAAs (MAGE-A3, MAGE-C2, tyrosinase, and gp100) and TriMix (CD40L, CD70, and caTLR4) combined with ipilimumab on 39 pretreated patients with unresectable histologically confirmed stage 3 or 4 melanoma.